iX Biopharma Ltd. (SGX:42C)

Market Cap	129.06M
Revenue (ttm)	7.77M
Net Income (ttm)	-10.14M
Shares Out	n/a
EPS (ttm)	-0.01
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,538,700
Average Volume	10,802,320
Open	0.1350
Previous Close	0.1350
Day's Range	0.1350 - 0.1390
52-Week Range	0.0150 - 0.1440
Beta	n/a
RSI	66.97
Earnings Date	Feb 4, 2026

About iX Biopharma

iX Biopharma Ltd., a specialty pharmaceutical and nutraceutical company, develops, manufactures, and commercializes therapies for the treatment of acute and breakthrough pain, and other health conditions in Singapore, the United States, China, and Australia. The company operates through Specialty Pharmaceutical and Nutraceutical segments. It offers Wafesil and Silcap for the treatment of male erectile dysfunction; and Xativa, a sublingual cannabidiol wafer, as well as Hypera, a sublingual tetrahydrocannabinol wafer for chronic pain, anxiety, an...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2004
• Employees: 35
• Stock Exchange: Singapore Exchange
• Ticker Symbol: 42C

Financial Performance

In 2025, iX Biopharma's revenue was 7.77 million, an increase of 30.34% compared to the previous year's 5.96 million. Losses were -10.14 million, -6.05% less than in 2024.